Suzhou Zelgen Biopharmaceuticals Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2009-03-18
- Employees
- 867
- Market Cap
- -
- Website
- https://www.zelgen.com
Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 118
- Registration Number
- NCT03886415
- Locations
- 🇨🇳
The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China
Topical rhThrombin as an Adjunct to Hemostasis During Segmental Hepatectomy
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 84
- Registration Number
- NCT03611426
- Locations
- 🇨🇳
Zhiwei Li, Hangzhou, Zhejiang, China
Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 17
- Registration Number
- NCT03607188
- Locations
- 🇨🇳
Shanghai Eastern Hospital, Shanghai, Shanghai, China
A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 204
- Registration Number
- NCT03602495
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
The Tolerance, Pharmacokinetics of Jaktinib in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: placebo
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 126
- Registration Number
- NCT03314402
- Locations
- 🇨🇳
First Hospital of Jilin University, Chang Chun, Jilin, China
Donafenib for Previously Treated Metastatic Colorectal Cancer
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 536
- Registration Number
- NCT02870582
- Locations
- 🇨🇳
the 307th Hospital of Chinese People's Liberation Army, Beijing, Beijing, China
🇨🇳West China Hospital Sichuan, Chengdu, Sichuan, China
Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Phase 2
Completed
- Conditions
- Differentiated Thyroid Cancer
- Interventions
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT02870569
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT02698111
- Locations
- 🇨🇳
Cancer Hospital of Medical College, Beijing, Beijing, China
Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 668
- Registration Number
- NCT02645981
- Locations
- 🇨🇳
The PLA 81 Hospital, Nanjing, Jiangsu, China
🇨🇳West China Hospital Sichuan University, Chengdu, Sichuan, China
Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 47
- Registration Number
- NCT02489916
- Locations
- 🇨🇳
West China Hospital,SCU, Chengdu, Sichuan, China